BW 587C

Drug Profile

BW 587C

Latest Information Update: 06 Dec 2000

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antithrombotics; Prostaglandins; Small molecules
  • Mechanism of Action Platelet aggregation inhibitors; Prostaglandin D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 06 Dec 2000 Profile reviewed but no significant changes made
  • 23 Sep 1998 No-Development-Reported for Thrombosis in United Kingdom (Unknown route)
  • 21 Aug 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top